SCHEMBL984394

SCHEMBL984394

CCOc1ccc(C2=NN(C(=O)Cc3ccc(OC)cc3)CC2)cc1

nearest known ligand 0.70

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.70
ALDH1A1 P00352 2/20 0.70
RAB9A P51151 2/20 0.70
HPGD P15428 2/20 0.70
MAOB P27338 3/20 0.53
MAPT P10636 2/20 0.47
ABCB1 P08183 1/20 0.45
ABCC1 P33527 1/20 0.45
POLB P06746 2/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
NPC1 O15118 1/20 0.44
HSD17B10 Q99714 2/20 0.44
NPSR1 Q6W5P4 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
LMNA P02545 1/20 0.43
TSHR P16473 1/20 0.43
MAPK1 P28482 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL980150 0.93 ALDH1A1 (0.76) SMN1; SMN2ALDH1A1RAB9AHPGDMAOB
SCHEMBL981747 0.90 ALDH1A1 (0.56) SMN1; SMN2ALDH1A1RAB9AHPGDMAOB
SCHEMBL982974 0.90 RAB9A (0.58) SMN1; SMN2ALDH1A1RAB9AHPGDMAOB
SCHEMBL979306 0.88 ALDH1A1 (0.60) SMN1; SMN2ALDH1A1RAB9AHPGDMAOB
SCHEMBL982366 0.87 SMN1; SMN2 (0.68) SMN1; SMN2ALDH1A1RAB9AHPGDMAOB
SCHEMBL980195 0.87 SMN1; SMN2 (0.68) SMN1; SMN2ALDH1A1RAB9AHPGDMAOB
SCHEMBL979286 0.87 ALDH1A1 (0.71) SMN1; SMN2ALDH1A1RAB9AHPGDMAOB
SCHEMBL981950 0.87 SMN1; SMN2 (0.64) SMN1; SMN2ALDH1A1RAB9AHPGDMAOB
SCHEMBL981227 0.85 ALDH1A1 (0.65) SMN1; SMN2ALDH1A1RAB9AHPGDMAOB
SCHEMBL981326 0.83 MAOB (0.65) SMN1; SMN2ALDH1A1RAB9AHPGDMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1917248-B1 1-ACYLDIHYDROPYRAZOL DERIVATIVES MERCK PATENT GMBH (DE) 2015-08-19 EP claimed
US-7875644-B2 tyrosine kinase inhibitors, in particular Met kinase; antitumor agents;1-(Benzo-1,2,5-thiadiazol-5-ylmethylcarbonyl)-3-(2,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole; leukemia, carcinomas MERCK PATENT GMBH (DE) 2011-01-25 US claimed
US-20080249095-A1 1-Acyldihydropyrazole Derivatives MERCK PATENT GESELLSCHAFT (DE) 2008-10-09 US claimed
EP-1917248-B1 1-ACYLDIHYDROPYRAZOL DERIVATIVES MERCK PATENT GMBH (DE) 2015-08-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249095-A1 1-Acyldihydropyrazole Derivatives MET, FLT3, ERBB3 SMN1; SMN2 4245/4885ALDH1A1 399/4885RAB9A 2347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.